Bristol Myers Squibb has announced a significant partnership with Hengrui Pharma, one of China's leading drugmakers, to develop and test new drugs. This collaboration, which could be worth billions, involves Bristol sending four of its experimental drugs to China for early-stage clinical trials conducted by Hengrui, along with joint efforts to discover additional new drugs.
Michael Baran from Affinity Asset Advisors highlighted that this deal is notable for its reciprocal nature, suggesting a shift in how U.S. drugmakers view collaboration with Chinese firms. Historically, U.S. companies have primarily licensed drugs developed in China, but this partnership indicates a more integrated approach to drug development across borders.
Data from DealForma shows that over half of large pharmaceutical companies' licensing deals this year have originated from China, a significant increase from previous years. Lieven Van der Veken from McKinsey noted that Bristol's strategy acknowledges the advantages of developing drugs in China, where costs and timelines are more favorable.
Chen Yu from TCGX emphasized that the industry is undergoing a transformation, with early drug development increasingly shifting to China, potentially mirroring trends seen in manufacturing.
While there are differing opinions on whether this trend benefits or harms the U.S. biopharmaceutical sector, there is consensus that China's role in drug development is becoming more prominent and is likely to continue growing